GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Twist Bioscience
How did Twist Bioscience transform DNA synthesis?
Twist Bioscience applied semiconductor manufacturing to DNA synthesis, shrinking reactions onto silicon chips to cut reagent use by 99.8% and massively boost throughput. Founded in 2013 in San Francisco, it aimed to make synthetic DNA affordable and scalable.
The company scaled from a disruptive startup to an industrial leader, reporting > $313 million revenue in fiscal 2024 and targeting $400 million by end of 2025. Its offerings span synthetic genes and NGS enrichment tools, underpinning the bioeconomy. Twist Bioscience Porter's Five Forces Analysis
What is the Twist Bioscience Founding Story?
Twist Bioscience was incorporated in April 2013 by Emily Leproust, Bill Banyai, and Bill Peck to tackle high-cost, low-throughput DNA synthesis using a silicon-based, microfluidic platform that aimed to scale high-fidelity synthetic DNA manufacturing.
Founding Story
The founders combined genomics, chemistry, and engineering expertise to commercialize a silicon platform for oligos, gene fragments, and libraries, backed by venture capital to move from prototype to production.
- Incorporated April 2013 by Emily Leproust, Bill Banyai, and Bill Peck — answering the question 'when was Twist Bioscience founded and by whom'
- Raised a $9.1 million Series A led by Arch Venture Partners to fund silicon-based DNA synthesis scale-up
- Initial MVPs: high-fidelity synthetic genes, oligo pools, and libraries aimed at research institutions and biotech firms
- Operated initially from a small San Francisco facility focused on depositing phosphoramidite chemistry onto silicon with precision
Twist Bioscience history shows an early focus on solving synthesis bottlenecks in drug discovery and agriculture by leveraging microfluidics and silicon manufacturing to disrupt incumbent DNA synthesis providers; see a related write-up on Marketing Strategy of Twist Bioscience.
Complete Twist Bioscience Strategy Bundle
- 6 Full Frameworks, 1 Company – All Pre-Researched
- Each Framework Fully Sourced with Real Company Data
- Built for Strategy Courses, Case Studies & MBA Programs
- Adapt to Your Assignment – No Starting from Scratch
- 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's
What Drove the Early Growth of Twist Bioscience?
Following its 2013 launch, Twist Bioscience entered rapid technological maturation and market expansion, moving to commercial-scale production by 2015 and securing major partnerships that validated its platform.
Commercial-scale production
By 2015 Twist Bioscience began commercial shipping of synthetic genes to early adopters, marking a key phase in the company's history and scaling manufacturing capacity.
DNA data storage validation
In 2016 Twist supplied 10 million DNA strands for a Microsoft–University of Washington project, demonstrating extreme-density storage potential and earning broader scientific validation.
Product portfolio expansion
Expansion into NGS target enrichment opened diagnostics and clinical research revenue streams, allowing capture of higher-margin sales beyond basic oligo supply.
Capital raises and IPO
Funding included a $61 million Series D in 2016 and ~$60 million in 2017; the company IPO'd on NASDAQ in October 2018 (ticker TWST), raising ~$70 million at $14/share.
Growth Strategy of Twist Bioscience
Geographic and customer diversification
Post-IPO expansion built international sales offices in Europe and Asia; by 2019 the company served over 1,000 customers, including major pharma partners.
Shift to integrated partnerships
Late 2018 launch of Twist Biopharma signaled a strategic move from component supplier to integrated discovery partner for biopharma, supporting collaborations with firms such as Takeda and Bayer.
From PESTLE Factors to Full Strategy Bundle
- PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
- Every Strategic Angle Covered – Nothing Left to Research
- Pre-filled with Company-Specific Research
- No Missing Sections for Your Case Study
- One Download Covers Your Entire Company Analysis
What are the key Milestones in Twist Bioscience history?
Milestones, Innovations and Challenges trace Twist Bioscience history from its founding through capacity expansion, platform patents, DNA data storage demos and early legal and market pressures that shaped operational discipline and path to profitability.
| Year | Milestone |
|---|---|
| 2013 | Company founded to commercialize a silicon-based DNA synthesis platform and begin scaling synthetic DNA production |
| 2020 | Settled trade-secret litigation with Agilent for $22.5 million without admission of wrongdoing |
| 2023 | Factory of the Future in Wilsonville, Oregon became fully operational, doubling production capacity |
| 2023 | Launched Express Genes service offering synthetic DNA in as little as five business days |
| 2024 | Recorded first quarter of positive adjusted EBITDA in the core business, continued through early 2025 |
Twist has secured hundreds of patents around its silicon platform and commercially advanced DNA data storage, demonstrating multi-millennium archival potential. The company also leveraged platform strengths into high-margin offerings like antibody discovery and NGS to improve unit economics and revenue mix.
Silicon-based DNA Synthesis
Proprietary silicon platform underpins scalable, high-fidelity oligo production and is covered by hundreds of patents.
Factory of the Future
Wilsonville facility doubled capacity in 2023 and enabled faster lead times and higher throughput.
Express Genes
Service launched to deliver synthetic DNA in as little as five business days, targeting rapid research workflows.
DNA Data Storage
Demonstrated ability to encode and preserve digital information in DNA with projected longevity of thousands of years.
Antibody Discovery Platforms
Expanded into high-margin discovery services to diversify revenue and improve gross margins.
Patent Portfolio
Hundreds of issued and pending patents protect core chemistry, instruments and workflows.
Twist navigated major challenges including the Agilent trade-secret suit settled in 2020 and a 2022 short-seller report that challenged manufacturing margins and technology credibility. Leadership responded with transparent reporting, cost controls and focus on profitable segments, which helped secure investor confidence and improved financials into 2024–2025.
Legal Settlement Impact
2020 settlement required payment of $22.5 million, prompting stronger IP and compliance controls and a temporary cash impact.
Market Skepticism
2022 short-seller allegations pressured stock and required detailed financial disclosures to rebut claims and restore credibility.
Competition from Enzymatic Synthesis
Emerging enzymatic DNA synthesis startups intensified competition, necessitating ongoing technology investment to sustain cost and quality advantages.
Operational Scaling
Doubling capacity in 2023 required capital expenditure and process validation to ensure consistent margins at scale.
Profitability Transition
Achieving consecutive quarters of positive adjusted EBITDA in 2024–early 2025 addressed long-standing investor concerns about the path to sustainable profitability.
Resilience and Discipline
Cost controls and focus on high-margin services reinforced operational discipline and supported continued revenue growth.
For additional context on market positioning and target segments see Target Market of Twist Bioscience
Twist Bioscience Business Model + Strategy Bundle
- Ideal for Essays, Case Studies & Slides
- Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
- Company-Specific Content Already Organized
- One Bundle Replaces Days of Independent Research
- Buy the Bundle Once. Use Across All Your Assignments
What is the Timeline of Key Events for Twist Bioscience?
Timeline and Future Outlook: a concise timeline of Twist Bioscience history highlighting key milestones from its 2013 founding to 2025 commercialization milestones, and a forward-looking view on AI integration, DNA data storage scale-up, and financial targets through 2026 and beyond.
| Year | Key Event |
|---|---|
| 2013 | Founded in San Francisco by Emily Leproust, Bill Banyai, and Bill Peck, initiating the Twist Bioscience founding story focused on high-throughput DNA synthesis. |
| 2015 | Initial commercial launch of synthetic gene products, marking the company’s first broad market offerings in synthetic biology. |
| 2016 | Entered a landmark DNA data storage partnership with Microsoft to explore archival storage using synthetic DNA. |
| 2018 | Successful IPO on NASDAQ raising $70,000,000 and launch of Twist Biopharma to target biologics discovery. |
| 2020 | Settled litigation with Agilent and pivoted significant capacity toward COVID-19 research tools and diagnostics supply. |
| 2022 | Opened a 110,000-square-foot Wilsonville manufacturing facility to scale DNA production and improve cost structure. |
| 2023 | Launched Express Genes, significantly reducing turnaround times for gene constructs and accelerating customer workflows. |
| 2024 | Reported record revenue of $313,000,000 with 43% gross margins, reflecting improved unit economics and scale. |
| 2025 | Planned early-access launch of DNA data storage commercial solutions and expanded AI-driven antibody design services. |
Industrializing biology through scale
Twist Bioscience company background centers on converting DNA synthesis into an industrial platform, lowering per-base costs and enabling applications from R&D to therapeutics.
DNA data storage commercialization
Following the Microsoft partnership and 2025 early-access offerings, the company targets scaling archival storage from megabytes toward gigabyte-class demonstrations by 2026.
AI-driven design and therapeutics
Twist is expanding AI-enabled antibody design and sequence optimization services, aiming to shorten discovery timelines and capture higher-margin biologics markets.
Financial and market trajectory
Analysts project the synthetic biology market CAGR > 20% through 2030; Twist’s 2024 performance and manufacturing scale position it to outpace peers while leadership targets full GAAP profitability.
For additional detail on revenue mix and commercialization strategy see Revenue Streams & Business Model of Twist Bioscience
From Five Forces to Full Company Analysis
- Includes SWOT, PESTLE, BMC, BCG and 4P's
- Pre-Researched with Company-Specific Data
- Best Value for a Complete Analysis
- Ready to Adapt for Your Case Study
- Ready for Essays and Slidesd
- What is Competitive Landscape of Twist Bioscience Company?
- What is Growth Strategy and Future Prospects of Twist Bioscience Company?
- How Does Twist Bioscience Company Work?
- What is Sales and Marketing Strategy of Twist Bioscience Company?
- What are Mission Vision & Core Values of Twist Bioscience Company?
- Who Owns Twist Bioscience Company?
- What is Customer Demographics and Target Market of Twist Bioscience Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.